One Kansas City child is battling cancer and a broken femur, but he isn't alone.

Doctors have found a gentler treatment for children whose leukaemia has come back, which could boost survival and quality of ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Recent advances in cancer treatment are transforming outcomes for patients, from Australia's push to eliminate cervical cancer to breakthroughs in blood and bone marrow cancers. CAR T-cell therapy is ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Carvykti is a B-cell maturation antigen-directed genetically modified autologous chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has approved Carvykti ® ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

The EU Health Technology Assessment (HTA) Regulation, which began phasing in from January 2025, introduced a new Joint Clinical Assessment (JCA) process to streamline and harmonize the comparative ...